Liège, 30 March 2012 - Uteron Pharma successfully completed a 14 million EUR capital increase. This new equity round enables Uteron Pharma to further finance its strong growth ambitions as a specialist in female healthcare.

Read full press release here: Uteron PR Capital Increase

May 2011 - Saffelberg Investments sells its 40% equity stake in Altachem NV to German market leader LINDAL Group.

Saffelberg entered the capital of Altachem (http://www.altachem.com/pages/news_press.html) in 2008, and successfully managed to advance and professionalize the company, appointing Koen Claerbout as new CEO thus laying the foundations for long-term sustainable growth. In May 2011, Saffelberg has reached an agreement, together with the other shareholders, to divest its stake to German market leader Lindal Group (http://www.lindalgroup.com/) - thus contributing to a further consolidation of the aerosol valves industry worldwide.

Also see article in Trends magazine:  Trends BELSPEED - 30 Sept 2010

Brussels, 30 September 2010 - Belspeed NV (http://www.belspeed.eu), a leading European player in fashion logistics with Belgian roots has entered a new era. The historical founders/shareholders have sold 100% of the shares to a new management team, working in partnership with Saffelberg Investments. 

Also see article in De Standaard :  DS Uteron Pharma - 28 April 2010

Belgian subsidiary of The Descartes Systems Group Inc. acquires 96,17% of Porthus' outstanding shares.

Read more here :  Porthus Press Release - 16 March 2010

Jos Sluys & Luc Osselaer on 2 years Saffelberg Investments.

Read full article here:  De Tijd - Jos Sluys & Luc Osselaer - 27 Mar 2010 

Jos Sluys talks about the investment philosophy behind Saffelberg Investments.

Read full article here:  Trends interview Jos Sluys - 7 Jan 2010

SAFFELBERG INVESTMENTS BECOMES STRATEGIC FINANCIAL PARTNER

Brussels, 3 November 2009 - CDM Group (www.cdm.be) with headquarters in Overijse - Belgium, is a technological leader in noise and vibration control systems in building, industry and railway applications and pioneering in this niche market since 1951.  In order to aggressively pursue its growth strategy, the Group has now attracted Saffelberg Investments as a strategic financial partner.

Brussels, 8 July 2009 - Gemaco Group (www.gemaco-group.com) has strengthened its leading market position in the promotional merchandising sector by attracting Saffelberg Investments (www.saffelberg.com) as shareholder and strategic partner. With this transaction, Saffelberg has now become a 45% shareholder of the group. Managing Director Olivier Somers, together with the current management team, will remain at the helm of the group. KBC Securities successfully closed the transaction.

Alken, 6 0ctober 2008. PharmaNeuroBoost N.V (PNB), based in Alken, Belgium, is set to raise EUR 6.5 M, of which EUR 2.5 M from Saffelberg Investments (Jos Sluys), EUR 2 M from Biovest (Rudi Mariën) and EUR 2 M from KBC Private Equity. The funds raised will be used to carry out further research aiming at market authorization of PNB's two lead products PNB01 and PNB02.